The Incidence and Risk of Vein Infusion Phlebitis After Intravenous Infusion of Proton Pump Inhibitors

Risk Assessment and Incidence of Vein Infusion Phlebitis After Intravenous Infusion of Proton Pump Inhibitors

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04658758

Acronym

VeinIPP

Enrollment

200

Registered

2020-12-08

Start date

2020-12-04

Completion date

2022-11-30

Last updated

2025-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vein Infusion Phlebitis

Keywords

vein infusion phlebitis, proton pump inhibitor therapy, intravenous infusion, ulcer bleeding, aging

Brief summary

Intermittent or continuous proton pump inhibitor (PPI) therapy are recommended for high-risk bleeding ulcers according to the French Society of Gastroenterology. The prevalence of incidence of vein infusion phlebitis after PPI intravenous infusion is high in geriatric acute ward (about 10% of severe vein infusion phlebitis). The primary of objective of the study is to determinate the prevalence of vein infusion phlebitis after PPI intravenous infusion in aging people. The secondary of objective of the study if to determinate the factors of risk of vein infusion phlebitis.

Detailed description

This is a multicenter observational study. 5 centers will participate to the study. Aging patients undergoing PPI intravenous infusion therapy will be proposed to be enrolled in the study. Paramedical observation will be performed during 5 days for each enrolled patients.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

70 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients aged \> 70 years; * Undergo intravenous continuous or intermittent proton pump inhibitor therapy; * Patients being informed and not opposed to the study.

Exclusion criteria

* Existing vein infusion phlebitis before the PPI infusion by intravenous route; * Under guardianship or curators; * Covered by french AME health system.

Design outcomes

Primary

Measure	Time frame	Description
Occurence of infusion phlebitis	at day-5	The Visual Infusion Phlebitis Scale will be used to define.

Secondary

Measure	Time frame	Description
Factors of risk of vein infusion phlebitis	Throughout of the study, an average of 1 year	To determinate risk factors for vein infusion phlebitis.

Countries

France

Outcome results